Financials data is unavailable for this security.
View more
Year on year Avalo Therapeutics Inc had revenues fall -89.34% from 18.05m to 1.92m, though the company grew net income from a loss of 41.66m to a smaller loss of 31.54m.
Gross margin | 64.19% |
---|---|
Net profit margin | -4,488.60% |
Operating margin | -6,660.35% |
Return on assets | -54.66% |
---|---|
Return on equity | -- |
Return on investment | -529.15% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Avalo Therapeutics Inc fell by 5.77m. Cash Flow from Financing totalled 25.04m or 1,301.56% of revenues. In addition the company used 30.68m for operations while cash used for investing totalled 133.00k.
Cash flow per share | -14.96 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -2.08 |
---|---|
Tangible book value per share | -12.24 |
More ▼
Balance sheet in USDView more
Current ratio | 0.9948 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼